VectivBio Holding AG

VectivBio Holding AG (VECT) priced its initial public offering on Apr 9, 2021 at $17.00 per share, raising $127.5M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $578.2M. BofA Securities was lead-left underwriter, joined by Leerink Partners and Credit Suisse. Cooley advised the company and Latham & Watkins advised the underwriters.

VectivBio Holding AG is a clinical-stage biopharmaceutical company developing treatments for severe rare conditions, mainly gastrointestinal disorders. Its product candidate apraglutide, a long-acting GLP-2 peptide analog, is being developed first for short bowel syndrome.

Status

IPO

Ticker

VECT

Exchange

Nasdaq Global Market

Priced

Apr 9, 2021

IPO price

$17.00

Raised

$127.5M

Market cap at IPO price

$578.2M

First filed

Mar 19, 2021

Underwriters

BofA Securities, Leerink Partners and Credit Suisse

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

Switzerland

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.